Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura, 3 Pad. G, 40139, Bologna, Italy.
J Headache Pain. 2019 Mar 12;20(1):27. doi: 10.1186/s10194-019-0979-y.
Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and in the heart. We reviewed the current evidence on the role of CGRP in the cardiovascular system in order to understand the possible short- and long-term effect of CGRP blockade with monoclonal antibodies in migraineurs.In physiological conditions, CGRP has important vasodilating effects and is thought to protect organs from ischemia. Despite the aforementioned cardiovascular implication, preventive treatment with CGRP antibodies has shown no relevant cardiovascular side effects. Results from long-term trials and from real life are now needed.
降钙素基因相关肽（CGRP）是一种在偏头痛病理生理学中起关键作用的神经肽。CGRP 的阻断是偏头痛患者的一个新的治疗靶点。CGRP 及其受体不仅分布在中枢和外周神经系统，也分布在心血管系统，包括血管和心脏。我们回顾了 CGRP 在心血管系统中的作用的现有证据，以便了解偏头痛患者使用单克隆抗体阻断 CGRP 可能产生的短期和长期影响。在生理条件下，CGRP 具有重要的血管舒张作用，被认为可以保护器官免受缺血的影响。尽管存在上述心血管影响，但 CGRP 抗体的预防性治疗并未显示出相关的心血管副作用。现在需要来自长期试验和真实生活的数据。
